Skip to content
Evigrade
CriticalSelective 5-HT1B/1D serotonin receptor agonist×Triptan, selective 5HT1B/1D receptor agonist

Updated · Methodology

Mechanism

Rizatriptan and zolmitriptan are selective agonists of 5-HT1B and 5-HT1D serotonin receptors, and stimulation of these receptors constricts cranial blood vessels (rizatriptan and zolmitriptan summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Their effects add up, and according to the Spanish rizatriptan SmPC this raises the risk of coronary artery constriction and hypertensive effects (AEMPS, section 4.5). The US labels of both drugs give possible additive vasospastic effects as the reason for the contraindication (US Food and Drug Administration, FDA, section 7.3). The documents give no data on either drug changing the levels of the other.

Symptoms

Agonists of 5-HT1B/1D receptors have been associated with coronary artery spasm and, rarely, with myocardial ischaemia and infarction (rizatriptan summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). Rizatriptan can cause transient chest tightness and pain, sometimes intense and spreading to the throat, and zolmitriptan heaviness, tightness, pain or pressure in the throat, neck, limbs and chest. Both drugs can raise blood pressure and cause palpitations. Very rarely, zolmitriptan causes coronary vasospasm, angina, myocardial infarction and ischaemia or infarction of the bowel and spleen with bloody diarrhoea or abdominal pain (rizatriptan and zolmitriptan SmPCs, AEMPS, sections 4.4 and 4.8). Life-threatening ventricular tachycardia and ventricular fibrillation have been reported within a few hours of 5-HT1 agonists, and on rare occasions hypertensive crisis with acute impairment of organ systems. Spasm of other arteries causes ischaemia of the limbs and bowel (rizatriptan and zolmitriptan labels, US Food and Drug Administration, FDA, sections 5.2, 5.5 and 5.8).

Management

The combination is contraindicated. The Spanish rizatriptan summary of product characteristics (SmPC) names zolmitriptan among the 5-HT1B/1D receptor agonists that must not be used with rizatriptan (Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5), and the Spanish zolmitriptan SmPC contraindicates zolmitriptan with other 5-HT1B/1D receptor agonists (AEMPS, section 4.3). The US labels of both drugs contraindicate a second 5-HT1 agonist within 24 hours (US Food and Drug Administration, FDA, sections 4 and 7.3). Keep at least 24 hours between the two drugs, in either order (zolmitriptan SmPC, AEMPS, section 4.5; FDA labels, section 4). The Spanish rizatriptan SmPC gives no such interval. If the first rizatriptan dose does not help, do not take a second dose for the same attack (rizatriptan SmPC, AEMPS, section 4.2). According to the zolmitriptan SmPC, a second dose is unlikely to help in the same attack (AEMPS, section 4.2). Rizatriptan is contraindicated in moderately severe or severe hypertension and in untreated mild hypertension, and zolmitriptan in moderate or severe hypertension and in uncontrolled mild hypertension (AEMPS, section 4.3). Monitor blood pressure during zolmitriptan treatment (zolmitriptan label, FDA, section 5.8). If chest pain or other signs of cardiac ischaemia appear, withhold further doses until the patient has been assessed (rizatriptan and zolmitriptan SmPCs, AEMPS, section 4.4). Stop the triptan if heart rhythm disturbances occur (FDA labels, section 5.2). Taking acute migraine drugs on 10 or more days a month can make headaches more frequent (FDA labels, sections 5.6 and 17). If medication overuse headache is suspected, interrupt treatment (rizatriptan and zolmitriptan SmPCs, AEMPS, section 4.4).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Rizatriptan

Other interactions with Zolmitriptan